

Dr. Reddy's Laboratories Ltd. 8-2-337, Road No. 3, Banjara Hills, Hyderabad - 500 034, Telangana, India.

CIN: L85195TG1984PLC004507

Tel :+91 40 4900 2900 Fax :+91 40 4900 2999 Email : mail@drreddys.com www.drreddys.com

October 15, 2018

Corporate Relationship Department
BSE Limited
Dalal Street, Fort
Mumbai – 400 001

Fax Nos.: 022-22723121 / 22723719 / 22722037 / 22722039

**Scrip Code:** 500124

National Stock Exchange of India Ltd. "Exchange Plaza" Bandra-Kurla Complex, Bandra (East), Mumbai – 400 051 Fax Nos.: 022-26598120/ 26598237/

26598238

Scrip Code: DRREDDY-EQ

Dear Sirs,

Sub: Press Release

Please find enclosed a Press Release on "Dr. Reddy's Laboratories receives approval for Aspirin and Extended-Release Dipyridamole Capsules in the U.S. Market".

This is for your information.


With regards,

Sandeep Poddar Company Secretary

Encl: As above

CC:- New York Stock Exchange Inc.(Stock Code :RDY)

## **Press Release**



DR. REDDY'S LABORATORIES LTD.

8-2-337, Road No. 3, Banjara Hills, Hyderabad - 500034. Telangana, India. CONTACT
INVESTOR RELATIONS MEDIA

MEDIA RELATIONS

SAUNAK SAVLA

saunaks@drreddys.com (Ph: +91-40-49002135) CALVIN PRINTER
<a href="mailto:calvinprinter@drreddys.com">calvinprinter@drreddys.com</a>
(Ph: +91-40- 49002121)

## Dr. Reddy's Laboratories receives approval for Aspirin and Extended-Release Dipyridamole Capsules in the U.S. Market

Hyderabad, India, October 15, 2018

For Immediate Release

Hyderabad, India and Princeton, NJ, USA. October 15, 2018— Dr. Reddy's Laboratories Ltd ((BSE: 500124, NSE: DRREDDY, NYSE: RDY, along with its subsidiaries together referred to as "Dr. Reddy's") today announced receipt of approval for Aspirin and Extended-Release Dipyridamole Capsules, a therapeutic equivalent generic version of Aggrenox (aspirin and extended-release dipyridamole) Capsules in the United States market from the U.S. Food and Drug Administration (USFDA). The Company is working towards launching the product.

The Aggrenox brand and generic had U.S. sales of approximately \$183 million MAT for the most recent twelve months ending in August 2018 according to IMS Health\*.

Dr. Reddy's Aspirin and Extended-Release Dipyridamole Capsules is available in 25 mg/200 mg strength with 60 count bottle size.

Aggrenox is a registered trademark of Boehringer Ingelheim.

\*IMS National Sales Perspective: Retail and Non-Retail MAT August 2018 RDY-1018-218

About Dr. Reddy's: Dr. Reddy's Laboratories Ltd. (BSE: 500124, NSE: DRREDDY, NYSE: RDY) is an integrated pharmaceutical company, committed to providing affordable and innovative medicines for healthier lives. Through its three businesses - Pharmaceutical Services & Active Ingredients, Global Generics and Proprietary Products – Dr. Reddy's offers a portfolio of products and services including APIs, custom pharmaceutical services, generics, biosimilars and differentiated formulations. Our major therapeutic areas of focus are gastrointestinal, cardiovascular, diabetology, oncology, pain management and dermatology. Dr. Reddy's operates in markets across the globe. Our major markets include – USA, India, Russia & CIS countries, and Europe. For more information, log on to: <a href="https://www.drreddys.com">www.drreddys.com</a>.

Disclaimer: This press release may include statements of future expectations and other forward-looking statements that are based on the management's current views and assumptions and involve known or unknown risks and uncertainties that could cause actual results, performance or events to differ materially from those expressed or implied in such statements. In addition to statements which are forward-looking by reason of context, the words "may", "will", "should", "expects", "plans", "intends", "anticipates", "believes", "estimates", "predicts", "potential", or "continue" and similar expressions identify forward-looking statements. Actual results, performance or events may differ materially from those in such statements due to without limitation, (i) general economic conditions such as performance of financial markets, credit defaults, currency exchange rates, interest rates, persistency levels and frequency / severity of insured loss events (ii) mortality and morbidity levels and trends, (iii) changing levels of competition and general competitive factors, (iv) changes in laws and regulations and in the policies of central banks and/or governments, (v) the impact of acquisitions or reorganization, including related integration issues.

The company assumes no obligation to update any information contained herein.



